Abstract:e21555 Background: Treatment paradigms in advanced melanoma are evolving with the success of new targeted and immunotherapies. The purpose of this study is to explore the outcomes associated with neoadjuvant therapy for advanced melanoma at our institution. Methods: We performed a retrospective analysis of all patients diagnosed with melanoma who received neoadjuvant immunotherapy for locally and regionally advanced primary or recurrent disease at an NCI-designated Comprehensive Cancer Center. Demographic information, primary tumor staging and characteristics, treatment regimen, clinical and pathological responses, and radiologic reports were collected. Results: The analytic cohort consisted of 14 patients who either completed or are receiving neoadjuvant immunotherapy. 11 have a cutaneous primary and 3 have an unknown primary. Treatment regimens consisted of PD-1 inhibitor (n = 9), TVEC (n = 1), combination of PD-1 inhibitor and TVEC (n = 3) and combination of CCR2 and PD-1 inhibitors (n = 1). Prior therapy included Ipilimumab in 3 patients and radiation in 2 patients. 5 patients received neoadjuvant therapy for primary disease and 9 patients received neoadjuvant therapy for recurrent disease. 7 patients had overall clinical response (5 complete response (CR), 2 partial response (PR)), 3 patients had stable disease (SD) and 3 patients had progression. 8 patients underwent surgical resection after therapy, 4 of these patients had clinically SD, 1 patient had a PR and 3 patients had progression. Surgeries performed included excision of 2 primary and 2 recurrent sites, 5 lymph node dissections and 1 resection of in-transit disease. Median time to surgery from the start of immunotherapy was 7.5 months (range 0 - 14). 5 patients had a partial and 3 patients had a complete pathological response. 2 patients continued therapy after resection. An additional 6 patients are currently receiving immunotherapy with intent to undergo resection. Median follow-up time from diagnosis was 27 months (range 10 - 95). Conclusions: At our tertiary referral center select patients with locally and regionally advanced melanoma are considered for neoadjuvant immunotherapy with an overall response in 50% of patients. Further studies are currently pending which will likely validate our results.

Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma

Neoadjuvant therapy for resectable melanoma

The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma

Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Neoadjuvant therapy for melanoma: past, present, and future

Neoadjuvant therapy for melanoma: A critical appraisal

Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma

Neoadjuvant Therapy in Advanced Melanoma.

Precision Oncology in Melanoma: Changing Practices

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

Landscape of Neoadjuvant Therapy for Breast Cancer

Adjuvant immunotherapy for melanoma patients: progress and opportunities

Melanoma genotypes and phenotypes get personal

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Neoadjuvant Immunotherapy: A Promising New Standard of Care

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma